天圣制药集团股份有限公司 第五届监事会第十一次会议决议公告 证券代码：002872 证券简称：ST 天圣 公告编号：2023-043 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 天圣制药集团股份有限公司（以下简称"公司"）第五届监事会第十一次 会议于 2023 年 8 月 23 日以现场及通讯方式召开。2023 年 8 月 11 日，以电话及 电子邮件的通知方式发出会议通知。 本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由监事会主席钟 梅女士主持。董事会秘书和其他高级管理人员列席了本次会议。本次会议的召 集、召开及表决程序符合《中华人民共和国公司法》、《天圣制药集团股份有 限公司章程》及相关法律法规的规定。 二、监事会会议审议情况 （一）审议通过了《关于公司<2023 年半年度报告全文及摘要>的议案》 经审核，监事会认为董事会编制和审核公司 2023 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2023-046 天圣制药集团股份有限公司 关于 2023 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 （二）本次计提资产减值准备的资产范围、总金额和拟计入的报告期间 经公司对截至 2023 年 6 月 30 日合并报表范围内的资产进行全面清查和资产 减值测试后，公司计提有关资产减值准备合计 908.14 万元。本次计提资产减值 准备计入的报告期间为 2023 年 1 月 1 日至 2023 年 6 月 30 日。具体情况如下： | | 2023 年 1-6 | 月计提 占 | | 2022 年度经审计归属于母 | | | --- | --- | --- | --- | --- | --- | | 资产名称 | 减值准备金额（万 | | 公司所有者的净利润（绝对值） | | | | | 元） | | | 的比例 | | | 应收账款坏账损失 | | 76.27 | | | 0.84% | | 其他应收款坏账损失 | | 593.40 | | | 6.55% | | 存货 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2023-041 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易所 股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司"或 "天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 一、关于实行其他风险警示事项及主要原因 控股股东刘群涉嫌侵占公司资金，由于刘群和李洪的部分涉案财物已扣押、 冻结、查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交 易所股票上市规则》相关规定，公司股票交易被实施其他风险警示。公司于 2019 年 6 月 5 日披露了《关于公司股票交易被实行其他风险警示的公告》；并 分别于 2019 年 7 月 5 日、2019 年 8 月 3 日、2019 年 9 月 5 日、2019 年 10 月 9 日、2019 年 11 月 5 日、2019 年 12 月 5 日、2020 年 1 月 ...

证券代码：002872 证券简称：ST 天圣 天圣制药集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|--------------------------------|------------------------------|--------------------------| | | | | 编号：2023-001 | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 √ | 业绩说明会 | | | 投资者关系活动 | | | | | | □新闻发布会 □ | 路演活动 | | | 类别 | | | | | | □现场参观 | | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 线上参与公司 ST | 天圣 2022 | 年度报告网上说明会的投资 | | 人员姓名 | | 者 | | | 时间 | 2023 年 05 月 16 | 日（星期二）下午 15:00-17:00 | | | 地点 | "天圣制药投资者关系"微信小程序 | | | | 上市公司接待人 | 董事 ...

投资者依据提示，授权登入"天圣制药投资者关系"小程序，即可参与交 流。 天圣制药集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日 在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022 年年度报告》及其 摘要。为便于广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 5 月 16 日（星期二）下午 15:00-17:00 采用网络远程的方式在"天圣制 药投资者关系"小程序举行 2022 年度网上业绩说明会。 为广泛听取投资者的意见和建议，提前向投资者征集问题，提问通道自发 出公告之日起开放，投资者可提前进入"天圣制药投资者关系"小程序平台进 行提问。本次网上业绩说明会将采用网络远程的方式举行，投资者可通过以下 方式参与互动交流： 参与方式一：在微信小程序中搜索"天圣制药投资者关系"； 参与方式二：微信扫一扫以下二维码： 证券代码：002872 证券简称：ST 天圣 公告编号：2023-029 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 1 天圣制药集团股份有限公司 关于举行 202 ...

Financial Performance - Tiansheng Pharmaceutical reported a revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[1]. - The company has set a revenue target of RMB 1.5 billion for 2023, which reflects a growth forecast of 25%[1]. - The company's operating revenue for 2022 was ¥606,992,213.55, a decrease of 17.61% compared to ¥736,685,771.58 in 2021[22]. - The total revenue for 2022 was ¥606,992,213.55, a decrease of 17.61% compared to the previous year[55]. - The net profit attributable to shareholders was -¥90,563,424.65 in 2022, representing a decline of 33.56% from -¥67,805,395.08 in 2021[22]. - The company reported a net profit attributable to shareholders in Q4 2022 was -¥27,981,426.64, showing a significant loss compared to previous quarters[27]. - The company achieved a net profit of RMB 300 million, which is a 15% increase compared to the previous year[197]. - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to RMB 1.8 billion[198]. Research and Development - The company plans to invest RMB 200 million in R&D for new drug development in 2023, focusing on oncology and chronic diseases[1]. - Research and development expenses amounted to ¥34,269,400, an increase of 17.19% year-on-year[58]. - The company is focusing on expanding its product line and enhancing process quality through various new applications and approvals[74]. - The company plans to increase R&D investment in traditional Chinese medicine and chemical drugs, focusing on high-end and basic products, with a commitment to developing innovative drugs and health products[107]. - Research and development expenses increased by 10%, totaling RMB 150 million, focusing on innovative drug formulations[198]. Market Expansion - Tiansheng Pharmaceutical is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2023[1]. - The company plans to enhance its digital marketing efforts, aiming for a 50% increase in online sales channels[149]. - The company is expanding its market presence, targeting a 20% market share within the next three years[196]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[1]. Product Development - Tiansheng has successfully launched two new products in Q4 2022, contributing an additional RMB 100 million in revenue[1]. - New product launches are expected to contribute an additional RMB 200 million in revenue in the upcoming fiscal year[197]. - The company has approved multiple new products, including Lidocaine Hydrochloride Injection and Torasemide Injection, which are expected to positively impact performance[74]. Financial Management - The company has not declared any cash dividends for 2022, opting to reinvest profits into business expansion[1]. - The company has a robust marketing network, covering over 15,000 medical institutions, reflecting its strong market position and brand advantage[54]. - The company has established a comprehensive quality management system, ensuring that all materials undergo strict quality inspections, with non-compliant materials not allowed in production[46]. - The company has a structured training system in place, focusing on internal career development and professional skill enhancement for employees[165]. Risks and Challenges - The company faces potential risks including regulatory changes and market competition, which could impact future performance[1]. - The pharmaceutical industry faces significant policy risks, including stricter regulations and quality standards, which could impact future development[114]. - Price reductions in pharmaceuticals due to government policies and market competition pose risks to the company's profitability[118]. - The company is involved in a significant legal case regarding bribery, with a potential financial penalty of RMB 3.8 million[119]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of investor interests[126]. - The board of directors consists of 7 members, including 3 independent directors, and operates under strict governance rules[130]. - The company has implemented a transparent performance evaluation and incentive mechanism for its management team[132]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, and financial management[136][138]. Environmental Responsibility - The company adheres to environmental protection laws and industry standards during the production of small-volume injectables and traditional Chinese medicine extracts[180]. - The company has established a wastewater treatment station that operates normally, with wastewater primarily sourced from equipment and floor cleaning, ensuring compliance with discharge standards[184]. - The company has implemented strict environmental protection measures in all construction projects, ensuring compliance with environmental impact assessments[181]. - The total environmental protection investment for 2022 was CNY 554,055.65, including CNY 512,300 for operation and maintenance of environmental facilities, CNY 8,000 for hazardous waste disposal, and CNY 32,500 for testing fees[185].

Financial Performance - The company's revenue for Q1 2023 was ¥157,406,569.47, representing a 16.29% increase compared to ¥135,352,879.35 in the same period last year[5]. - The net loss attributable to shareholders was ¥15,891,842.97, a slight increase of 0.86% from a loss of ¥15,756,573.03 in the previous year[5]. - The net profit for the first quarter of 2023 was a loss of CNY 15,941,138.48, slightly improved from a loss of CNY 16,107,018.96 in the previous year[27]. - The total operating revenue for the first quarter of 2023 was CNY 157,406,569.47, an increase from CNY 135,352,879.35 in the same period last year, representing a growth of approximately 16.1%[26]. - The total operating costs for the first quarter of 2023 amounted to CNY 185,618,603.60, up from CNY 158,112,243.94, indicating an increase of about 17.5%[26]. - The total comprehensive income for the first quarter was -15,941,138.48 CNY, compared to -16,107,018.96 CNY in the previous period[28]. - Basic and diluted earnings per share were both -0.0500 CNY, slightly down from -0.0495 CNY in the previous period[28]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥41,342,239.54, a significant decline of 560.89% compared to a positive cash flow of ¥8,970,094.74 in the same period last year[5]. - Cash inflow from operating activities was 181,093,471.66 CNY, a decrease from 181,896,481.33 CNY year-over-year[30]. - Net cash outflow from operating activities was -41,342,239.54 CNY, compared to a positive inflow of 8,970,094.74 CNY in the previous period[31]. - Cash inflow from investing activities totaled 16,514,150.00 CNY, significantly down from 130,424,863.54 CNY in the previous period[31]. - Net cash outflow from investing activities was -49,364,825.51 CNY, compared to -91,517,616.88 CNY in the previous period[31]. - Cash inflow from financing activities was 169,800,000.00 CNY, up from 47,000,000.00 CNY in the previous period[31]. - Net cash inflow from financing activities was 85,321,749.71 CNY, compared to 12,815,643.92 CNY in the previous period[31]. - The ending cash and cash equivalents balance was 272,865,094.73 CNY, down from 299,103,683.75 CNY at the beginning of the period[31]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,980,922,616.16, showing a 0.37% increase from ¥2,969,827,475.68 at the end of the previous year[5]. - The total assets as of March 31, 2023, were CNY 2,980,922,616.16, compared to CNY 2,969,827,475.68 at the start of the year[25]. - The total liabilities increased to CNY 808,103,736.09 from CNY 782,234,793.97, reflecting a rise of approximately 3.3%[25]. - The company's cash and cash equivalents at the end of the first quarter were CNY 272,865,094.74, down from CNY 278,250,410.08 at the beginning of the year[23]. Borrowings and Financial Expenses - Short-term borrowings increased by 40.32% compared to the end of the previous year, primarily due to the reapplication for bank loans[9]. - The company reported a significant decrease in short-term borrowings, which rose to CNY 125,431,995.83 from CNY 89,393,118.06, indicating a rise of approximately 40.4%[25]. - The company's financial expenses decreased, while interest income increased due to the recognition of interest income from financial support provided to Changsheng Pharmaceutical[12]. Research and Development - The company's technology center was recognized as a National Enterprise Technology Center, enhancing its research and development capabilities[20]. - Research and development expenses for the first quarter were CNY 8,257,754.73, compared to CNY 7,291,377.71 in the previous year, showing an increase of about 13.3%[27]. Government Support and Investment Income - The company received government subsidies amounting to ¥4,611,341.12 during the reporting period, which contributed to its non-recurring gains[6]. - The company reported a 95.13% decrease in investment income compared to the previous year, primarily due to the lack of maturity of financial products during the reporting period[14]. Other Information - The weighted average return on net assets was -0.73%, slightly lower than -0.70% in the same period last year[5]. - The first quarter report was not audited[32]. - The company's inventory at the end of the first quarter was CNY 126,619,887.21, down from CNY 130,873,102.95 at the beginning of the year, reflecting a decrease of about 3.3%[24]. - The company plans to participate in the national drug centralized procurement, with its product Furosemide injection expected to win the bid[21].

证券代码：002872 证券简称：天圣制药 天圣制药集团股份有限公司 投资者关系活动记录表 编 号 ： 2018- 001 | --- | --- | --- | |---------------------|-----------------------------|------------------------------------------------------| | | | | | | □ □ | 特定对象调研 □分析师会议 媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | ☑其他（终止重大资产重组投资者说明会） | | 参与单位名称及 | 公司投资者 | | | 人员姓名 | | | | 时间 | 2018 年 7 月 3 日 | | | 地点 | 全景•路演天下（ | http://rs.p5w.net ） | | 上市公司接待人 | | 公司代董事长刘维先生、董事刘爽先生、董事会秘书王琴女 | | 员姓名 | | 士、财务总监王开胜先生及其他相关人员。 | | 投资者关系活动 | 主要问答： | | | ...

证券代码：002872 证券简称：天圣制药 天圣制药集团股份有限公司 投资者关系活动记录表 编 号 ： 2018- 002 | --- | --- | --- | |-------------------------|------------------------|------------------------------------------------------| | | | | | | ☑ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他（请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 彭伟华（受彭志红委托） | | | | | | | 时间 | 2018 年 12 月 | | | 地点 | 公司会议室 | | | 上市公司接待人 | | 公司代董事长刘维先生、董事刘爽先生、董事会秘书王琴女 | | 员姓名 | | 士、财务总监王开胜先生及其他相关人员。 | | 投资者关系活动 | 一、签署《承诺书》 | | | 主要内容介绍 | 二、 ...